Solaraze

Contusions, Pain, Photophobia + 54 more

Treatment

10 FDA approvals

20 Active Studies for Solaraze

What is Solaraze

Diclofenac

The Generic name of this drug

Treatment Summary

Diclofenac is a type of medication used to reduce pain and inflammation. It belongs to a class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs work by blocking the enzymes that produce prostaglandins, which cause inflammation and pain. Diclofenac is a popular choice for treating pain and inflammation from a variety of causes. It is often taken in combination with misoprostol to prevent stomach ulcers caused by the drug. Diclofenac was approved by the FDA in 1988 and is sold under the brand name Voltaren.

Voltaren

is the brand name

image of different drug pills on a surface

Solaraze Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Voltaren

Diclofenac

1988

767

Approved as Treatment by the FDA

Diclofenac, also called Voltaren, is approved by the FDA for 10 uses including Osteoarthritis of the Knee and Pain .

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Pain

Helps manage Pain

Postoperative Inflammatory Response

Chronic Pain

Helps manage Pain

Osteoarthritis (OA)

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Stomach Ulcer

Used to treat develop NSAID-induced gastric ulcers in combination with Misoprostol

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Osteoarthritis

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Rheumatoid Arthritis

Cataract Surgery

Effectiveness

How Solaraze Affects Patients

Diclofenac helps reduce inflammation, pain, and fever. However, it can also cause stomach ulcers by reducing the amount of protective mucus in the stomach.

How Solaraze works in the body

Diclofenac works to reduce pain and inflammation in the body by inhibiting the production of prostaglandins. Prostaglandins are molecules that have wide-ranging effects on pain and inflammation. They make nerves more sensitive, reduce the threshold for action potentials, and make blood vessels wider. In the long term, they reduce immune responses. Prostaglandins also activate thermoregulatory neurons in the brain, which increases body temperature and causes a fever. By preventing the production of prostaglandins, diclofenac combats all of these effects.

When to interrupt dosage

The recommended measure of Solaraze is contingent upon the identified ailment, including Joint Pain, Postoperative Inflammatory Response and Osteoarthritis (OA). The amount likewise fluctuates as per the mode of delivery (e.g. Cream; Kit; Solution or Kit; Oil; Solution / drops) featured in the table beneath.

Condition

Dosage

Administration

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Photophobia

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Postoperative

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Cataract Surgery

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Postoperative Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Rheumatoid Arthritis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Rheumatism

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Radiculopathy

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Postoperative Inflammatory Response

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Conjunctivitis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Acute Coryza

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

perioperative miosis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

radial keratotomy

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Actinic Keratosis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Arthralgia

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Primary Dysmenorrhoea

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Arthritis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Contusions

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Warnings

Solaraze Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Heart failure

Do Not Combine

Crohn's Disease

Do Not Combine

recent history of anal bleeding

Do Not Combine

Hemorrhagic Disorders

Do Not Combine

Gastritis

Do Not Combine

inflammatory lesions of the Rectum

Do Not Combine

active Gastrointestinal Bleeding

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

active Gastrointestinal Perforation

Do Not Combine

Duodenal Ulcer

Do Not Combine

Coronary Artery Bypass Grafting

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

Ulcerative Colitis

Do Not Combine

Liver Diseases

Do Not Combine

Stroke

Do Not Combine

Third trimester of pregnancy

Do Not Combine

Hematochezia

Do Not Combine

Kidney Failure

Do Not Combine

Kidney Failure

Do Not Combine

Anus

Do Not Combine

Ulcer

Do Not Combine

damaged skin

Do Not Combine

Gastric ulcer

Do Not Combine

Peptic Ulcer

Do Not Combine

Hyperkalemia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Diclofenac may interact with Pulse Frequency

There are 20 known major drug interactions with Solaraze.

Common Solaraze Drug Interactions

Drug Name

Risk Level

Description

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Diclofenac.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Diclofenac.

Cyclophosphamide

Major

The metabolism of Cyclophosphamide can be decreased when combined with Diclofenac.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Diclofenac.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Diclofenac.

Solaraze Toxicity & Overdose Risk

Overdosing on Voltaren can lead to symptoms such as fatigue, nausea, vomiting, upper abdominal pain, and bleeding from the digestive tract. In rare cases, patients may experience high blood pressure, kidney damage or failure, hypoventilation, or coma. Treatments for Voltaren overdose include inducing vomiting and activated charcoal, as long as the overdose occurred within the last 4 hours.

image of a doctor in a lab doing drug, clinical research

Solaraze Novel Uses: Which Conditions Have a Clinical Trial Featuring Solaraze?

491 active clinical trials are currently examining the potential of Solaraze to ameliorate Inflammation, argon laser trabeculoplasty and Osteoarthritis of the Knee.

Condition

Clinical Trials

Trial Phases

Inflammation

54 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 3, Phase 4

Osteoarthritis of the Knee

75 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Chronic Pain

122 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Early Phase 1, Phase 1

Rheumatoid Arthritis

56 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2, Phase 4

Postoperative Pain

20 Actively Recruiting

Phase 4, Phase 2, Phase 1, Phase 3, Not Applicable

Dysmenorrhea

1 Actively Recruiting

Not Applicable

Muscle Pain

3 Actively Recruiting

Phase 4, Not Applicable, Phase 2

Conjunctivitis

0 Actively Recruiting

Musculoskeletal System

1 Actively Recruiting

Not Applicable

corneal refractive surgery

0 Actively Recruiting

Postoperative Inflammatory Response

0 Actively Recruiting

Photophobia

3 Actively Recruiting

Not Applicable

Pain

3 Actively Recruiting

Not Applicable

Stomach Ulcer

0 Actively Recruiting

Rheumatism

0 Actively Recruiting

Juvenile arthritis

7 Actively Recruiting

Phase 2, Not Applicable, Phase 3

radial keratotomy

0 Actively Recruiting

Joints

0 Actively Recruiting

Pericarditis

2 Actively Recruiting

Phase 2, Phase 3

Acute Coryza

0 Actively Recruiting

Solaraze Reviews: What are patients saying about Solaraze?

5

Patient Review

11/27/2019

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I've been using this treatment for a month now and all the rough patches of keratosis on my face are gone. I've used it before for 90 days with the same success; however, after a couple months the sun damage begins to reappear. Need to check with doctor how often I can retreat with this product.

5

Patient Review

1/6/2017

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I followed my dermatologist's orders and used this for three months on my face. It was completely successful, though I did have to take some antihistamines for the severe irritation about halfway through. The next round of treatment (on my arms, chest, and legs) is not something I'm looking forward to but the results last long enough that it's worth it to me.

4

Patient Review

3/1/2022

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I've used Solaraze for 90 days now and it seems to have worked well! The only side effect I experienced was that my white hair turned yellow blonde. Not sure if this is common or not, but figured I'd mention it just in case.

4

Patient Review

9/16/2016

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I stuck with this treatment for two months, as it took that long to see any real results. But now the area where I was experiencing problems appears to have healed completely!

3.3

Patient Review

4/7/2014

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

Shortly after using this treatment on both of my forearms, I developed nickel-sized sores that took several weeks to heal. The sores also killed the pigment in my skin, so now there are white blotches on both of my forearms. I wish I had been warned about this potential side effect ahead of time!

3

Patient Review

8/27/2022

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I'm still seeing blemishes, despite using this product twice daily as directed.

2.7

Patient Review

1/1/2013

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

Unfortunately, I had a very negative reaction to this treatment. Three weeks in, I developed an intense itching rash with swelling and pustules. Additionally, my eyes swelled shut and I had blood and pus on my pillow. I had to go to emergency care and take steroids and antihistamines. I also needed antibiotics for a developing infection. So be careful if you have sensitive skin - I wasn't warned by the physician about this possibility.

2.7

Patient Review

11/9/2021

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I found that the cream made me anxious and gave me bad dreams, so I stopped using it before the recommended time was up. My mental health is more important to me than following the instructions on this medication. Thankfully, my anxiety levels returned to normal as soon as I stopped using Solarize.

2.3

Patient Review

11/30/2012

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

Solaraze did nothing for me except give me pimples and make my existing tinnitus worse.

2

Patient Review

8/30/2013

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I used this gel for four weeks and unfortunately started developing red patches, sores, and itchiness around my upper lip and nose. I'm discontinuing use in this area and hopefully it will heal without any scars. The other areas on my face healed well though.

2

Patient Review

4/10/2019

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

Unfortunately, I had a severe allergic reaction to this treatment. My face was swollen and covered in scabs and it was very itchy. I ended up having to go to the emergency room.

1.7

Patient Review

8/4/2014

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I was diagnosed with actinic keratosis and prescribed solaraze. I used it for two weeks, but my rash and dry skin area increased. So, I went back to the doctor; they said it showed that it was working... One week later, I developed a blister on my lip and lowered eyelid ballooned up—my eye was almost shut. The third doctor told me to stop using it and prescribed a moisturising cream.

1.7

Patient Review

10/11/2013

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

This product is way too expensive and didn't work at all.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about solaraze

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Solaraze do to your skin?

"The drug Solaraze works by destroying unstable skin cells and causing the immune system to repair the damaged skin. It contains a non-steroidal anti-inflammatory called Diclofenac, and another topical ingredient called hyaluronic acid (which helps tissue penetration of the drug into active sites)."

Answered by AI

What is Solaraze gel used to treat?

"Solaraze is a dermatological gel that is used to treat a skin problem known as actinic or solar keratosis. Solar keratosis is a skin condition that is caused by long-term sun exposure. If you are allergic to diclofenac or any of the ingredients of this medicine, you should not use Solaraze gel."

Answered by AI

How long should you use Solaraze for?

"Before using the medication, wash and dry your hands. Apply a thin layer of the medication to the affected skin, rub it in well, and do this 2 times every day. In most cases, you will need to do this for 60 to 90 days."

Answered by AI

Does Solaraze require prescription?

"Solaraze is a cream that is used to treat warts that have grown on sun-exposed areas of the body. It may be used alone or with other medications. Solaraze belongs to a class of drugs called Topical Skin Products."

Answered by AI

Clinical Trials for Solaraze

Image of University Center for Ambulatory Surgery in Somerset, United States.

Infusion Pump for Postoperative Pain

18+
All Sexes
Somerset, NJ

This study will be a pragmatic, prospective cluster randomized trial, where clusters will formed based on sequential 2 week time increments across the study recruitment period.. Patients 18 years or older undergoing ACL reconstruction, open shoulder labrum or rotator cuff surgery, arthroscopic rotator cuff repair, proximal or distal patellar realignment surgery, open knee arthrotomy cases (i.e. inside out meniscus repair, osteochondral allograft transplantation (OCA), meniscal allograft transplantation (MAT)) at University Center for Ambulatory Surgery, LLC (UOA) will be reviewed for eligibility. Once identified, potential study subjects will be asked whether they are interested in participating in the project. If the patient agrees, the subject will be given the informed consent to read and sign. Objectives: The primary objective is to compare the effectiveness of postoperative infusion pain pump versus preoperative nerve block in reducing visual analog pain scores/numerical pain rating scale (VAS/NPRS) in the postoperative period. The second objective is to evaluate the requirement of narcotic and non-narcotic analgesic medications between the two groups. Hypotheses: Use of continuous infusion pain pump or single shot peripheral block will result in similar post-operative pain control after outpatient sports medicine surgical cases.

Phase 4
Recruiting

University Center for Ambulatory Surgery

Image of Montana State University in Bozeman, United States.

Haskap Berries for Exercise Performance Recovery

18 - 35
All Sexes
Bozeman, MT

The purpose of this clinical trial is to determine how certain food items affect oxidative stress, inflammation, and performance recovery from exercise induced muscle damage in a resistance trained population. The main questions The investigators aim to answer are the following: * Do Haskaps speed the recovery of oxidative stress and inflammation markers after an intense lower body workout in resistance trained adults? * Do Haskaps speed the recovery of performance measures after an intense lower body workout in resistance trained adults? * The data collected in this investigation may also be used to ask additional questions not yet identified. For example, the investigators may use the stored samples to evaluate how the blood metabolites of participants differ before and after intense exercise. These additional questions are called secondary analyses. Please note that no genetic analysis will be conducted and racial and ethnic differences among participants will not be used in any secondary analyses. Researches will compare Haskap juice to a color, flavor and carbohydrate matched placebo to see if Haskaps speed recovery in inflammation, oxidative stress and performance. * Participants will be asked to drink either Haskap juice or placebo and follow a low polyphenolic diet * Participants will perform an intense resistance workout * Participants will have their blood drawn before and after the workout * Performance will be analyzed at 24, 48 and 72 hours after the workout

Recruiting
Paid Trial

Montana State University

Mary P Miles

Image of University of North Carolina at Chapel Hill in Chapel Hill, United States.

Pain Medicines for Period Pain in Crohn's Disease

18 - 44
Female
Chapel Hill, NC

The purpose of this pilot study is to prepare for a larger study that will compare the effectiveness and safety of two common pain medications, ibuprofen and acetaminophen, to help treat period cramps in women with Crohn's disease. The goal of this study is to identify any challenges in running a larger study. The investigators will track how many people sign up for the study, how well participants follow the study plan, how many people stay in the study, and whether they are able to complete all the study activities, such as taking the medication, submitting samples, and filling out surveys. During the study, participants will undergo a screening visit that includes a blood draw, physical exam, pregnancy test, stool testing, and complete surveys about Crohn's disease and menstrual cycles. Once this visit is complete, the rest of the study will occur at home. Participants will be assigned to take either ibuprofen or acetaminophen to help treat period cramps for four menstrual cycles in a row. Participants will take ibuprofen for two cycles and acetaminophen for two cycles. Participants will know which medication is being taken at any given time, but the order in which they take the medications will be randomly assigned. Before each menstrual cycle, participants will submit a stool sample and fill out a short (\<1 minute) electronic survey. When participants develop period cramps, they will take the assigned medication for three days and fill out short (\<1 minute) electronic surveys about their cramps. After participants finish taking the medication for three days, they will submit another stool sample and fill out two more short (\<1 minute) electronic surveys. After have completing this process for four menstrual cycles, a remote interview with a researcher to give feedback on the study will be conducted.

Waitlist Available
Has No Placebo

University of North Carolina at Chapel Hill

Erica J Brenner, MD, MSCR

Image of AltaSciences, Inc in Cypress, United States.

SBS-147 Safety Study

18 - 55
All Sexes
Cypress, CA

This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results. The study includes two parts: Single-Dose Group, where Participants receive SBS-147 or placebo one time. Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.

Phase 1
Waitlist Available

AltaSciences, Inc

Jeff Reich, MD

Sparian Biosciences, Inc

Have you considered Solaraze clinical trials?

We made a collection of clinical trials featuring Solaraze, we think they might fit your search criteria.
Go to Trials
Image of Byers Eye Institute in Palo Alto, United States.

LLM-Based Education for Cataract Surgery

18+
All Sexes
Palo Alto, CA

Patients with cataracts disease need to choose what type of artificial lens will go into their eye prior to surgery date. Some lenses are standard and are usually covered by insurance. Other "premium" lenses have various benefits such as reducing the need for glasses but usually require out-of-pocket costs. The combined busy outpatient clinic and complexity of artificial lens choices in the ever-changing world of cataract surgery tends to lead patients confused about their available lens options. There is an abundance of educational material present in premium lenses, however these are limited by accessibility and are standardized at single educational levels. Therefore in the present study, we want to test whether giving patients a short LLM powered AI-guided explanation from Custom GPT from OpenAI of lens options prior to their consultation with their doctor can improve visit efficiency, physician explanation and patient understanding of lens options. We will compare two groups: standard of care versus standard of care plus AI education. The LLM in this study is intended to provide supplemental information about premium intraocular lens(IOLs) options to study participants, and is no means supposed to replace a health care professional in the diagnosis, cure, treatment, and/or mitigation of disease. Study is analogous to giving a verified health pamphlet to a patient for them to view and learn different IOL options, in other words, facilitating patient understanding of their options. The LLM will be trained by several health care professionals and MD specialists to provide sufficient instructions. Sources will include verified online resources and MD information. The investigators hope to learn if a large language model-based educational tool can improve visit efficiency, physician explanation and patient understanding of intraocular lens options. New knowledge of this study could guide how cataract counseling is delivered in the future and may help clinics spend more time on individualized questions instead of repeating generic information.

Waitlist Available
Has No Placebo

Byers Eye Institute

Robert T Chang, MD

Image of University of New Brunswick in Fredericton, Canada.

Mediterranean Diet for Toddler Health

24 - 36
All Sexes
Fredericton, Canada

Toddlerhood (ages 2-3) is a critical window when the gut microbiome is still developing and eating habits are being established. Yet, many Canadian toddlers eat diets high in sugar and salt, which may affect long-term health. This study will test whether a MED diet can improve dietary inflammation, gut health, and body composition in toddlers and whether a tailored nutrition education program for parents can help families maintain healthy eating patterns. In this study, toddlers will be randomly assigned to a 3-week MED diet or their usual diet. Families in the MED diet group will receive free meal boxes for the 3 weeks, plus guidance from a nutrition researcher through a structured education program. The standard diet group will continue their regular diet with general nutrition advice. Researchers will collect dietary information, body composition assessments, and stool samples to measure gut microbiome composition and metabolites. This first study of a controlled diet intervention in toddlers, combining behavioral support, high-quality food provision, and advanced gut microbiome analysis, will help understand how early diet shapes lifelong eating habits and health, guiding public health strategies and precision nutrition approaches to prevent chronic disease from early life.

Waitlist Available
Has No Placebo

University of New Brunswick

Dr. Maryam Kebbe, PhD, CLC

Have you considered Solaraze clinical trials?

We made a collection of clinical trials featuring Solaraze, we think they might fit your search criteria.
Go to Trials

Have you considered Solaraze clinical trials?

We made a collection of clinical trials featuring Solaraze, we think they might fit your search criteria.
Go to Trials